IP Library Granted Patent US 8,076,456
Granted Patent B2
US 8,076,456 · App. 12/721,002 · Granted Dec 13, 2011

Fusion proteins comprising canine thymic stromal lymphopoietin protein and uses thereof

Assignee: Intervet Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,456
App. No.
12/721,002
Granted
Dec 13, 2011
Kind
B2
Abstract

The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.

Claims (19)

1. A fusion protein comprising a thymic stromal lymphopoietin protein (TSLP) or an antigenic fragment thereof, wherein said TSLP comprises an amino acid sequence that has 90% or greater identity to the amino acid sequence of SEQ ID NO: 2, excluding the 28 amino acid residue signal sequence; and

wherein said TSLP is cross-reactive with an antibody raised against the canine TSLP comprising the amino acid of SEQ ID NO: 2.

2. The fusion protein of claim 1 wherein the TSLP binds to an epitope-specific canine TSLP antibody.

3. The fusion protein of claim 1 , wherein the TSLP is a canine TLSP.

4. The fusion protein of claim 3 , wherein the canine TSLP comprises amino acid residues 29-155 of SEQ ID NO: 2.

5. A fusion protein comprising an antigenic fragment of a canine TSLP, wherein said antigenic fragment comprises the amino acid sequence of SEQ ID NO:64.

6. The fusion protein of claim 5 , wherein said antigenic fragment further comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-63 and 65-101, or a combination of two or more thereof; and wherein said antigenic fragment binds to an epitope-specific canine TSLP antibody.

7. A nucleic acid molecule encoding a fusion protein comprising a thymic stromal Iymphopoietin protein (TSLP) or an antigenic fragment thereof wherein said TSLP corn rises an amino acid sequence that has 90% or greater identity to the amino acid sequence of SEQ ID NO: 2, excluding the 28 amino acid residue signal sequence; and wherein said TSLP is cross-reactive with an antibody raised against the canine TSLP comprising the amino acid of SEQ ID NO: 2.

8. The nucleic acid molecule of claim 7 , wherein the TSLP is a canine TLSP; and wherein the canine TSLP comprises amino acid residues 29-155 of SEQ ID NO: 2.

9. The nucleic acid molecule of claim 8 that comprises the nucleotide sequence of SEQ ID NO: 1.

10. An expression vector that comprises the nucleic acid molecule of claim 7 .

11. An expression vector that comprises the nucleic acid molecule of claim 8 .

12. An expression vector that comprises the nucleic acid molecule of claim 9 .

13. A nucleic acid molecule encoding a fusion protein comprising an antigenic fragment of a canine TSLP, wherein said antigenic fragment comprises the amino acid sequence of SEQ ID NO:64.

14. The nucleic acid molecule of claim 13 , wherein said antigenic fragment further comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-63 and 65-101, or a combination of two or more thereof; and wherein said antigenic fragment binds to an epitope-specific canine TSLP antibody.

15. An expression vector that comprises the nucleic acid molecule of claim 13 .

16. An expression vector that comprises the nucleic acid molecule of claim 14 .

17. A method of producing a fusion protein comprising culturing a host cell in a suitable culture medium, wherein said host cell comprises the expression vector of claim 11 , and wherein the fusion protein is expressed.

18. The method of claim 17 further comprising isolating the fusion protein from the cultured host cell or the culture medium.

Assignments (1)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
Continuity (3)
Division 11954143 · Dec 11, 2007
Provisional Application 60875135 · Dec 14, 2006
Related Publication 20110033478A1 · Feb 10, 2011